BR112012022669A2 - composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. - Google Patents
composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.Info
- Publication number
- BR112012022669A2 BR112012022669A2 BR112012022669A BR112012022669A BR112012022669A2 BR 112012022669 A2 BR112012022669 A2 BR 112012022669A2 BR 112012022669 A BR112012022669 A BR 112012022669A BR 112012022669 A BR112012022669 A BR 112012022669A BR 112012022669 A2 BR112012022669 A2 BR 112012022669A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic composition
- antigen
- fhbp
- vaccine
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. a presente invenção se refere ao campo de composições imunogênicas e vacinas de neisserial, sua fabricação e o uso de tais composições na medicina. em particular, a presente invenção se refere a composições e métodos que envolve o antígeno de proteína de ligação do fator h (fhbp). os presente inventores reconheceram que fhbp é fator h (fhbp). os presente inventores reconheceram que fhbp é deficientemente expressado em cepas de neisserial de imunotipo l2 (e complexo clonal st11) e vacinas que compreendem fhbp podem ser tornados mais eficazes contra as ditas cepas pela formulação da vacina com um antígeno adicional que pode evocar proteção contra estas cepas.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31257410P | 2010-03-10 | 2010-03-10 | |
US31255010P | 2010-03-10 | 2010-03-10 | |
US31258210P | 2010-03-10 | 2010-03-10 | |
US31280410P | 2010-03-11 | 2010-03-11 | |
US31279210P | 2010-03-11 | 2010-03-11 | |
US31279910P | 2010-03-11 | 2010-03-11 | |
PCT/EP2011/053631 WO2011110635A1 (en) | 2010-03-10 | 2011-03-10 | Immunogenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012022669A2 true BR112012022669A2 (pt) | 2017-02-14 |
Family
ID=43983531
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022669A BR112012022669A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
BR112012022688A BR112012022688A2 (pt) | 2010-03-10 | 2011-03-10 | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
BR112012022676A BR112012022676A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022688A BR112012022688A2 (pt) | 2010-03-10 | 2011-03-10 | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
BR112012022676A BR112012022676A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit |
Country Status (7)
Country | Link |
---|---|
US (4) | US20130004530A1 (pt) |
EP (3) | EP2544712A1 (pt) |
JP (4) | JP2013521770A (pt) |
CN (3) | CN102869377A (pt) |
BR (3) | BR112012022669A2 (pt) |
CA (3) | CA2792689A1 (pt) |
WO (3) | WO2011110634A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1179072A2 (en) | 1999-05-19 | 2002-02-13 | Chiron S.P.A. | Combination neisserial compositions |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
EP2886551A3 (en) | 2008-02-21 | 2015-09-23 | Novartis AG | Meningococcal fhbp polypeptides |
EP2411048B1 (en) | 2009-03-24 | 2020-05-06 | GlaxoSmithKline Biologicals SA | Adjuvanting meningococcal factor h binding protein |
JP2013521770A (ja) * | 2010-03-10 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
EP3831406B1 (en) | 2010-08-23 | 2024-06-05 | Wyeth LLC | Stable formulations of neisseria meningitidis rlp2086 antigens |
AU2011300409B2 (en) | 2010-09-10 | 2015-03-26 | Wyeth Llc | Non-lipidated variants of Neisseria meningitidis ORF2086 antigens |
EP2823312B1 (en) | 2012-03-08 | 2019-08-07 | GlaxoSmithKline Biologicals SA | In vitro potency assay for protein-based meningococcal vaccines |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MX351993B (es) | 2012-03-09 | 2017-11-03 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
CN104428008B (zh) * | 2012-05-24 | 2020-10-09 | 美国政府(由卫生和人类服务部的部长所代表) | 多价脑膜炎球菌缀合物及制备缀合物的方法 |
NZ630133A (en) * | 2012-06-14 | 2016-10-28 | Novartis Ag | Vaccines for serogroup x meningococcus |
CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
CN104248755A (zh) * | 2013-10-30 | 2014-12-31 | 普莱柯生物工程股份有限公司 | 一种副猪嗜血杆菌病疫苗组合物及其制备方法和应用 |
HUE052293T2 (hu) | 2014-02-28 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Módosított fHbp meningococcus-polipeptidek |
EP3169358A1 (en) | 2014-07-17 | 2017-05-24 | GlaxoSmithKline Biologicals S.A. | Meningococcus vaccines |
CN106795208A (zh) | 2014-07-17 | 2017-05-31 | 葛兰素史密丝克莱恩生物有限公司 | 修饰的脑膜炎球菌fHbp多肽 |
RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
AU2016262823A1 (en) * | 2015-05-18 | 2017-12-07 | Universita' Degli Studi Di Trento | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
US20190282684A1 (en) * | 2016-09-02 | 2019-09-19 | Glaxosmithkline Biologicals, S.A. | Vaccines for neisseria gonorrhoeae |
JP7010961B2 (ja) | 2017-01-31 | 2022-02-10 | ファイザー・インク | 髄膜炎菌組成物およびその方法 |
BR102020013216A2 (pt) * | 2020-06-26 | 2022-03-08 | Instituto Butantan | Processo de obtenção de vesículas apresentadoras de antígenos (vaa) que possibilita o acoplamento de um ou mais antígenos |
MX2023009728A (es) * | 2021-02-19 | 2023-08-30 | Sanofi Pasteur Inc | Vacuna recombinante meningococica b. |
CN113896799B (zh) * | 2021-09-10 | 2023-07-21 | 江苏南农高科技股份有限公司 | 一种融合蛋白、融合蛋白疫苗及其制备方法、应用 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
DE3071552D1 (en) | 1979-09-21 | 1986-05-22 | Hitachi Ltd | Semiconductor switch |
US4271147A (en) | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
EP0449856B1 (en) | 1988-12-16 | 2001-09-12 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin mutants and pneumococcal vaccines made therefrom |
WO1992001460A1 (en) | 1990-07-16 | 1992-02-06 | The University Of North Carolina | Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins |
JP3532563B2 (ja) | 1990-08-23 | 2004-05-31 | ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル | Neisseria gonorrhoeaeおよびNeisseria meningitidis由来トランスフェリン結合蛋白質 |
US5912336A (en) | 1990-08-23 | 1999-06-15 | University Of North Carolina At Chapel Hill | Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5371186A (en) | 1991-02-11 | 1994-12-06 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
US5652211A (en) | 1991-02-11 | 1997-07-29 | Biosynth S.R.L. | Peptides for neutralizing the toxicity of Lipid A |
US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
FR2682041B1 (fr) | 1991-10-03 | 1994-01-14 | Pasteur Merieux Serums Vaccins | Vaccin contre les infections a neisseria meningitidis. |
EP0621886A1 (en) | 1992-01-13 | 1994-11-02 | Akzo Nobel N.V. | Crosslinking of rubbers with engineering plastics |
CA2129899C (en) | 1992-02-11 | 2011-01-04 | James J. Mond | Dual carrier immunogenic construct |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
ES2185658T3 (es) | 1993-05-18 | 2003-05-01 | Univ Ohio State Res Found | Vacuna para la otitis media. |
CN1267553C (zh) | 1993-11-08 | 2006-08-02 | 康诺特实验室有限公司 | 嗜血杆菌属转铁蛋白受体基因 |
US6361779B1 (en) | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ES2267100T5 (es) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | Oligonucleótidos inmunomoduladores. |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
PL323781A1 (en) | 1995-06-07 | 1998-04-27 | Biochem Vaccines Inc | Streptococco thermal shock proteins belonging to a family hsp70 |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
US6440701B1 (en) | 1996-03-08 | 2002-08-27 | Aventis Pasteur Limited | Transferrin receptor genes of Moraxella |
JP2000511411A (ja) | 1996-05-01 | 2000-09-05 | ザ ロックフェラー ユニヴァーシティ | 抗―肺炎球菌ワクチン用のコリン結合タンパク質 |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
FR2751000B1 (fr) | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
ES2277362T5 (es) | 1996-10-31 | 2014-12-18 | Human Genome Sciences, Inc. | Antígenos y vacunas de streptococcus pneumoniae |
CA2292838A1 (en) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Lactoferrin receptor genes of moraxella |
CA2297374A1 (en) | 1997-07-21 | 1999-01-28 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
IL134436A0 (en) | 1997-08-15 | 2001-04-30 | Univ Utrecht | Neisseria lactoferrin binding protein |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
WO1999051266A2 (en) | 1998-04-07 | 1999-10-14 | Medimmune, Inc. | Derivatives of pneumococcal choline binding proteins for vaccines |
GB9808734D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9811260D0 (en) | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
GB9814902D0 (en) | 1998-07-10 | 1998-09-09 | Univ Nottingham | Screening of neisserial vaccine candidates against pathogenic neisseria |
US6951652B2 (en) | 1998-07-29 | 2005-10-04 | Biosynth S.R.L. | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases |
GB9820003D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
BR9915543A (pt) | 1998-10-16 | 2001-08-14 | Fraunhofer Ges Forschung | Resistência a doenças por plantas mediada por patogenicidas moleculares |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
DK1127137T4 (da) | 1998-11-03 | 2014-02-10 | Nederlanden Staat | LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier |
WO2000055327A2 (en) * | 1999-03-12 | 2000-09-21 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
EP1179072A2 (en) | 1999-05-19 | 2002-02-13 | Chiron S.P.A. | Combination neisserial compositions |
WO2000078968A2 (en) | 1999-06-18 | 2000-12-28 | Elitra Pharmaceuticals, Inc. | Nucleotide sequences of moraxella catarrhalis genome |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
NZ520445A (en) | 2000-01-25 | 2004-02-27 | Univ Queensland | Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
JP2006506467A (ja) * | 2002-08-02 | 2006-02-23 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004094596A2 (en) * | 2003-04-16 | 2004-11-04 | Wyeth Holdings Corporation | Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
CA2550927A1 (en) * | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection |
PT2682126T (pt) * | 2005-01-27 | 2017-02-28 | Children`S Hospital & Res Center At Oakland | Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis |
WO2007144316A2 (en) * | 2006-06-12 | 2007-12-21 | Glaxosmithkline Biologicals Sa | Vaccine |
GB0700562D0 (en) * | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
WO2009016237A2 (en) * | 2007-08-02 | 2009-02-05 | Glaxosmithkline Biologicals Sa | Molecular typing of neisseria strains by determining the presence of genes involved in lipooligosaccharide (los) biosynthesis |
US9511131B2 (en) | 2008-03-10 | 2016-12-06 | Children's Hospital & Research Center Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
RU2477145C2 (ru) * | 2008-05-30 | 2013-03-10 | ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
GB0819633D0 (en) * | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
EP2411048B1 (en) * | 2009-03-24 | 2020-05-06 | GlaxoSmithKline Biologicals SA | Adjuvanting meningococcal factor h binding protein |
BR112012010531A2 (pt) * | 2009-10-27 | 2019-09-24 | Novartis Ag | "polipeptídeos de modificação meningocócica fhbp" |
JP2013521770A (ja) * | 2010-03-10 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
US9473463B2 (en) | 2014-07-29 | 2016-10-18 | Combined Conditional Access Development & Support, LLC | Control word and associated entitlement control message caching and reuse |
-
2011
- 2011-03-10 JP JP2012556521A patent/JP2013521770A/ja active Pending
- 2011-03-10 JP JP2012556522A patent/JP2013521326A/ja active Pending
- 2011-03-10 CA CA2792689A patent/CA2792689A1/en not_active Abandoned
- 2011-03-10 WO PCT/EP2011/053630 patent/WO2011110634A1/en active Application Filing
- 2011-03-10 WO PCT/EP2011/053631 patent/WO2011110635A1/en active Application Filing
- 2011-03-10 CA CA2792683A patent/CA2792683A1/en not_active Abandoned
- 2011-03-10 EP EP11707192A patent/EP2544712A1/en not_active Withdrawn
- 2011-03-10 EP EP11708449A patent/EP2544714A1/en not_active Withdrawn
- 2011-03-10 JP JP2012556523A patent/JP2013521327A/ja active Pending
- 2011-03-10 CN CN2011800231068A patent/CN102869377A/zh active Pending
- 2011-03-10 US US13/583,064 patent/US20130004530A1/en not_active Abandoned
- 2011-03-10 BR BR112012022669A patent/BR112012022669A2/pt not_active IP Right Cessation
- 2011-03-10 US US13/583,163 patent/US20130011429A1/en not_active Abandoned
- 2011-03-10 US US13/583,314 patent/US9567377B2/en active Active
- 2011-03-10 BR BR112012022688A patent/BR112012022688A2/pt not_active IP Right Cessation
- 2011-03-10 CN CN2011800220453A patent/CN103002910A/zh active Pending
- 2011-03-10 BR BR112012022676A patent/BR112012022676A2/pt not_active IP Right Cessation
- 2011-03-10 CN CN2011800231104A patent/CN102869378A/zh active Pending
- 2011-03-10 CA CA2792687A patent/CA2792687A1/en not_active Abandoned
- 2011-03-10 EP EP11707193A patent/EP2544713A1/en not_active Withdrawn
- 2011-03-10 WO PCT/EP2011/053632 patent/WO2011110636A1/en active Application Filing
-
2016
- 2016-12-06 US US15/370,450 patent/US20170209562A1/en not_active Abandoned
-
2017
- 2017-02-02 JP JP2017017175A patent/JP2017114874A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20130045231A1 (en) | 2013-02-21 |
EP2544713A1 (en) | 2013-01-16 |
JP2017114874A (ja) | 2017-06-29 |
US20130004530A1 (en) | 2013-01-03 |
WO2011110635A1 (en) | 2011-09-15 |
EP2544712A1 (en) | 2013-01-16 |
JP2013521326A (ja) | 2013-06-10 |
US20130011429A1 (en) | 2013-01-10 |
WO2011110634A1 (en) | 2011-09-15 |
US9567377B2 (en) | 2017-02-14 |
CN102869377A (zh) | 2013-01-09 |
US20170209562A1 (en) | 2017-07-27 |
CN102869378A (zh) | 2013-01-09 |
CA2792687A1 (en) | 2011-09-15 |
BR112012022676A2 (pt) | 2019-09-24 |
EP2544714A1 (en) | 2013-01-16 |
WO2011110636A1 (en) | 2011-09-15 |
CA2792683A1 (en) | 2011-09-15 |
JP2013521770A (ja) | 2013-06-13 |
CN103002910A (zh) | 2013-03-27 |
JP2013521327A (ja) | 2013-06-10 |
BR112012022688A2 (pt) | 2018-05-22 |
CA2792689A1 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012022669A2 (pt) | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. | |
BR112012022800A2 (pt) | composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica | |
EP3916091A3 (en) | Dry powder composition comprising long-chain rna | |
EA201490512A1 (ru) | Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека | |
BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
BR112014004860A2 (pt) | composições de anticorpo contra vírus da influenza | |
EP3616716A3 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
EP3928800A3 (en) | Dry powder composition comprising long-chain rna | |
BR112013005427A2 (pt) | composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica. | |
BR112014018815A8 (pt) | Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis | |
BR112015024073A2 (pt) | Derivados de 3-acetilamino-1-(fenil-heteroaril- aminocarbonil ou fenil-heteroarilcarbonilamino) benzeno para tratamento de doenças hiperproliferativas | |
BR112012030616A2 (pt) | concentração de antígenos de vacina com liofilização. | |
BR112015017069A2 (pt) | processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo | |
BR112013018642A2 (pt) | vacinas e composições contra streptococcus pneumoniae | |
BRPI0918806A2 (pt) | composição compreendendo quitosana para administração ocular de vaninas em aves | |
BR112012030619A2 (pt) | concentração de antígenos de vacina influenza sem liofilização. | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
WO2013028555A3 (en) | Methods for weight loss and ketogenic compositions | |
BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
MX351380B (es) | Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino. | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
BR112018011331A2 (pt) | mutante de proteìna l1 de papillomavirus humano tipo 11 | |
BR112016025481A2 (pt) | alimentos, sistemas, métodos e estojos para provisão de substituição de eletrólito | |
BR112017013999A2 (pt) | ?composição derivada de uma bifidobactéria? | |
BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law | ||
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |